Bibliografia - www.migliorare l'erezione . net

SERVIZIO DELLA   PER TUTTI I PAZIENTI
CON PROBLEMATICHE UROLOGICHE
Consulta gratuitamente e senza impegno i nostri  specialisti
disponibili  on line 24 ore su 24 per ottenere qualsiasi  informazione sulla tua patologia
ed ogni chiarimento sui prodotti indicati nel sito  ed il loro utilizzo.

Trattamento della astenia sessuale  e della instabilità erettile  con L-arginina cloridrato associata ad integratori naturali: una alternativa al sildenafil.
F. Mantovani, E. Patelli
IRCSS "Ospedale maggiore di MIlano"
IV Giornate Andrologiche Italiane
Perugia 10-12-Settembre 1998

Migliorata efficacia di sildenafil nel trattamento della disfunzione erettiva dopo associazione con ginkgo biloba , arginina e magnesio: studio prospettico in doppio cieco.
B.Giammusso, M.Burrello, G. Salvia, P.Butera, M.Motta
Clinica Urologica Università Studi di Catania
Rivista di Urologia pratica  N° 3 Luglio - Settembre 2005

NIH Consensus Conference on Impotence. Consensus development panel on impotence. JAAAA 1993; 270: 83-90
Me KinlcyJB. Tiie woridwide prevalence and epidemica logy of erectile dysfunction. IntJ Impot Res 2000; 12 (Suppl. 4|: &] 1
Porazzini F, Mencfiini Fabris F Bortolotti A, et al. Fre-quency and determinants of erectile dysfunctions in Italy. Eur Urol 2000; 37: 43-9
Feldman FHA, Goldstein I, Hatzicfiristou DG, et al. Im and its medicai end psychosociol correlates: re-sults of tfie MassGcfiusetts male oging study. J  Urol 1994; 151: 54-61
Vicari E, Di Pino L, La Vignerà S, et al. Peak systolic ve-locity in patients witfi arterial erectile dysfunction and pe-ripfierol arterial disease. Int J Impot Res 2006; 18: 175-9
Kloner RA, Speakman M. Erectile dysfunction and athe-rosclerosis. Curr Atheroscler Rep 2002; 4: 397-401
Montorsi R Rovognoni PM, Galli s, et al. The artery size Uy potfiesis: 0 macrovoscular link bietween erectile dysfunction and coronory artery disease. Am J Cardici 2005; 9: 19M-23M
Tfiompson IM, Tangen CM, Goodman PJ. et al. Erectile dysfunction and subsequent cardiovasculcr disease. JAMA 2005; 294: 2996-3002
Elcckett gì. Erectile dysfunction predicts cordiovascular risk in men. BMJ 2008; 337: 2166
10. MorleyJE, Korenman sg, Kaiser FE, et al. Relation-ship of penile brocfiial pressure index to myocardiol infarction and cerebrovascular occidents in older men. AmJ Med 1988; 84: 445-8
1 1. Vicari E, Arcidiacono G, Di Pino L, et al. Incidence of extrcgenitcl vasculor disease in patients with erectile dysfunction and peripheral arterial disease. IntJ Impot Res 2005; 17: 277-82
Rosen RC, Riley A, Wagner G, et al. The Internationa Index for Erectile Function (IIEF]: a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-30
Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the In index of erectile function |IIEF-5) as a dio tool for erectile dysfunction. IntJ Impot Res 1999; 11:319-26
Musicki B, Burnett A. eNOS function and dysfunction in the penis. Exp BioI Med 2006;  231:1  54-65
Burnett A, Musicki B, Jin L, Bevilacqua T Nitric oxide/redox-based signolling as a theropeutic target ter penile disorders. Expert Opin Ther Targets 2006; 10: 445-57
Cervello A, Metz E. Is oxidotive stress the pathogenic mechanism underlying insulin resistcnce, diabetes, and cordiovascular disease? The common soii hypothesis re-visited. Arterioscler Thromb Vose BioI 2004; 24: 816-23
1 7. Carsson CC, Burnett AL, Levine lA, Nehra A. The effi-cocy of sildenafii cifrate (Viogral in clinical populations: an update. Urology 2002; 60: 12-27
Blonde L, Korenman SG, Siegal RL, et al. Sildenafii ci for treatment of erectile dysfunction is similarly ef-fective in men with t/pe 1 or type 2 diabetes mellitus. Diabetes 2000; 49 (Suppl. 11: A88
Park K, KuJH, Kim SW, PaickJS. Risk fadors in predic-ting a poor response to sildenafii citrale in elderly men with erectile dysfunction. BJU Int 2005; 95: 366-70
deTejada IS. Theropeutic strotegies for optimìzing PDE-5 inhibitor therapy in patients with erectile dysfunction con-sidered difficult or chcllenging to treot. Intern  J  Impot Res 2004; 16 (Suppl. l):S40-2
Moody JA, Vernet D, Laidiaw S, et al. Effects of long-term orai administration of L-arginine on the rat erectile re J Urol 1997; 158: 942-7
Vanella A, Russo A, Acquavivo A, et al. L-propionyl-carnitine as superoxide scavenger, ontioxidant, and DNA cleavcge protedor. Celi BioI Toxicol 2000; 16: 99-104
Bertelli A, Conte A, Ronca G, et al. Protective effect of pro-pionyl carnitine against peroxidotive damoge to arterial endothelium membrones. IntJ Tiss Reac 1991 ; 1  3:  41-3
Gentile V, Bertozzi MA. L-propionil-carnitino, L-arginina ed acido nicotinico in associazione nello disfunzione erettile del paziente diabetico. XXIV Congresso Nazio SIA; 7-10 novembre 2007: Ancona
Isidori AM, Lenzi A. L-propioniI carnitina, L-arginina e acido nicotinico in associazione nello disfunzione eret do varie cause. XXIII Convegno Medicina dello Ri 21-23 febbraio 2008: Abano Terme